^
    2ms
    LaserMucite: Laser Mucite ORL : Effectiveness of Laser Therapy for Mucositis Induced by a Radio-chemotherapy in Head and Neck Cancer (clinicaltrials.gov)
    P=N/A, N=97, Completed, Institut Cancerologie de l'Ouest | Unknown status --> Completed | Phase classification: P3 --> PN/A
    Trial completion • Phase classification
    2ms
    Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION) (clinicaltrials.gov)
    P2, N=36, Recruiting, Medical University of South Carolina | Initiation date: Jul 2026 --> Oct 2026
    Trial initiation date
    |
    NavDx®
    2ms
    Tissue context shapes distinct premalignant outcomes in a HPV16 E6/E7-mutant Pik3ca transgenic mouse model. (PubMed, Cancer Res Commun)
    Continuous oncogene expression was required for lesion maintenance, as doxycycline withdrawal reversed the proliferative phenotype, indicating a dynamic and reversible process...These findings demonstrate that identical oncogenic signals-HPV16 E6/E7 expression and PI3K activation-produce distinct premalignant outcomes depending on epithelial context. This work highlights the critical role of local microenvironmental factors in HPV-driven carcinogenesis and provides a platform to identify tissue-specific therapeutic vulnerabilities in HPV-associated cancers.
    Preclinical • Journal
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    PIK3CA mutation
    2ms
    HPV Serology and Circulating Viral DNA for Detection, Genotyping, and Measurement of Disease Burden in Oropharyngeal Cancer. (PubMed, Int J Cancer)
    Furthermore, HPV ctDNA but not HPV16 E6 antibody levels were positively associated with disease burden as determined by N-category, overall stage, and by tumor volume (ctDNA vs. volume, r = 0.48 p = 6.4e-12; E6 vs. volume, r = -0.079 p = 0.26). Overall, this is the largest cohort to compare HPV serology and HPV ctDNA results in OPC, and these findings highlight the potential for ctDNA to augment future strategies for blood-based early detection of HPV+ OPC.
    Journal
    |
    SafeSEQ HPV Test
    2ms
    Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies (clinicaltrials.gov)
    P1/2, N=51, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CD4 (CD4 Molecule)
    |
    PD-L1 negative
    |
    bintrafusp alfa (M7824) • Versamune HPV • PDS01ADC
    2ms
    Evaluating the Optimal Timing of Acupuncture for Managing Chemoradiation-induced Xerostomia in Patients With Head and Neck Cancers (clinicaltrials.gov)
    P=N/A, N=50, Not yet recruiting, National University Hospital, Singapore
    New trial
    2ms
    First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients (clinicaltrials.gov)
    P2, N=31, Active, not recruiting, Wake Forest University Health Sciences | Trial primary completion date: Jun 2026 --> Sep 2026
    Trial primary completion date
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel
    2ms
    Tumor Expression of Cerebellar Degeneration-Related Protein 2-Like in Rapidly Progressive Cerebellar Syndrome Associated With Oropharyngeal Squamous Cell Carcinoma. (PubMed, Cerebellum)
    Although anti-Yo/PCA-1-associated rapidly progressive cerebellar syndrome has rarely been reported in patients with SCC, tumor expression of CDR2L has not been demonstrated in such cases. This case supports the diagnostic value of examining tumor CDR2L expression in anti-Yo/PCA-1-associated rapidly progressive cerebellar syndrome with non-breast/non-gynecologic malignancies, especially SCC.
    Journal
    |
    CDR2 (Cerebellar Degeneration Related Protein 2)
    2ms
    High Dose Steroid Therapy (Prednisone or Methylprednisolone) for the Improvement of Symptoms of Late Radiation-Associated Lower Cranial Neuropathy in Oropharyngeal Cancer Survivors (clinicaltrials.gov)
    P1/2, N=35, Recruiting, M.D. Anderson Cancer Center | Active, not recruiting --> Recruiting
    Enrollment open
    |
    methylprednisolone sodium succinate
    2ms
    APG-157 in Locally Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P3, N=826, Not yet recruiting, Aveta Biomics, Inc.
    New P3 trial
    |
    cisplatin • carboplatin
    2ms
    A Phase 2 Feasibility Study Combining Pembrolizumab and Metformin in patients with Metastatic Head and Neck Cancer. (PubMed, Clin Cancer Res)
    The combination of metformin and pembrolizumab was well tolerated with mild GI-associated AEs and promising activity warranting further investigation in a randomized trial.
    P2 data • Journal
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1)
    |
    Keytruda (pembrolizumab) • metformin
    2ms
    Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer (clinicaltrials.gov)
    P1/2, N=120, Not yet recruiting, National Cancer Institute (NCI)
    New P1/2 trial
    |
    docetaxel • SX-682